Continuous veno-venous hemodiafiltration alleviates multiple organ dysfunction syndrome in dogs

References

• Matsuda, N., Hattori, Y. Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. J Pharmacol Sci 2006, 101, 189–198.
   PubMed Web of Science ®Google Scholar
• Gustot, T. Multiple organ failure in sepsis: prognosis and role of systemic inflammatory response. Curr Opin Crit Care 2011, 17, 153–159.
   PubMed Web of Science ®Google Scholar
• Baue, A.E. MOF, MODS, and SIRS: what is in a name or an acronym? Shock 2006, 26, 438–449.
   PubMed Web of Science ®Google Scholar
• Li, L., Pan, J., Yu, Y. Development of sorbent therapy for multiple organ dysfunction syndrome (MODS). Biomed Mater 2007, 2, R12–R16.
   PubMed Web of Science ®Google Scholar
• Ulloa, L., Tracey, K.J. The “cytokine profile”: a code for sepsis. Trends Mol Med 2005, 11, 56–63.
   PubMed Web of Science ®Google Scholar
• Tsiotou, A.G., Sakorafas, G.H., Anagnostopoulos, G., Bramis, J. Septic shock; current pathogenetic concepts from a clinical perspective. Med Sci Monit 2005, 11, RA76–RA85.
   PubMed Web of Science ®Google Scholar
• Ota, K. Dawn of hemodiafiltration. Contrib Nephrol 2011, 168, 1–4.
   PubMed Web of Science ®Google Scholar
• Yekebas, E.F., Eisenberger, C.F., Ohnesorge, H., Saalmüller, A., Elsner, H.A., Engelhardt, M., Gillesen, A., Meins, J., The, M., Strate, T., Busch, C., Knoefel, W.T., Bloechle, C., Izbicki, J.R. Attenuation of sepsis-related immunoparalysis by continuous veno-venous hemofiltration in experimental porcine pancreatitis. Crit Care Med 2001, 29, 1423–1430.
   PubMed Web of Science ®Google Scholar
• Hagiwara, S., Iwasaka, H., Hasegawa, A., Hidaka, S., Uno, A., Kaori, U., Uchida, T., Noguchi, T. Continuous hemodiafiltration therapy ameliorates LPS-induced systemic inflammation in a rat model. J Surg Res 2011, 171, 791–796.
   PubMed Web of Science ®Google Scholar
• Yonekawa, C., Nakae, H., Tajimi, K., Asanuma, Y. Combining continuous endotoxin apheresis and continuous hemodiafiltration in the treatment of patients with septic multiple organ dysfunction syndrome. Ther Apher Dial 2006, 10, 19–24.
   PubMed Web of Science ®Google Scholar
• Vinsonneau, C., Camus, C., Combes, A., Costa de Beauregard, M.A., Klouche, K., Boulain, T., Pallot, J.L., Chiche, J.D., Taupin, P., Landais, P., Dhainaut, J.F.; Hemodiafe Study Group. Continuous venovenous haemodiafiltration versus intermittent haemodialysis for acute renal failure in patients with multiple-organ dysfunction syndrome: a multicentre randomised trial. Lancet 2006, 368, 379–385.
   PubMed Web of Science ®Google Scholar
• Mao, H.J., Yu, S., Yu, X.B., Zhang, B., Zhang, L., Xu, X.R., Wang, X.Y., Xing, C.Y. Effects of coupled plasma filtration adsorption on immune function of patients with multiple organ dysfunction syndrome. Int J Artif Organs 2009, 32, 31–38.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang Z, Li Y, Liu J. A two hit dog model for the study of multiple organ dysfunction on syndrome. Chin J Emerg Med 2010;11:1183–1187.
   Google Scholar
• Hotchkiss, R.S., Karl, I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348, 138–150.
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock, L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007, 81, 584–592.
   PubMed Web of Science ®Google Scholar
• Moffitt, K.L., Martin, S.L., Walker, B. From sentencing to execution–the processes of apoptosis. J Pharm Pharmacol 2010, 62, 547–562.
   PubMed Web of Science ®Google Scholar
• Papathanassoglou, E.D., Movnihan, J.A., Dafni, O., Mantzoros, C.S., Ackerman, M.H. Association of proinflammatory molecules with apoptotic markers and survival in critically ill multiple organ dysfunction patients. Biol Res Nurs 2003, 5, 129–141.
   PubMedGoogle Scholar
• Joshi, V.D., Kalvakolanu, D.V., Cross, A.S. Simultaneous activation of apoptosis and inflammation in pathogenesis of septic shock: a hypothesis. FEBS Lett 2003, 555, 180–184.
   PubMed Web of Science ®Google Scholar
• Kennedy, L.J., Altet, L., Angles, J.M., Barnes, A., Carter, S.D., Francino, O., Gerlach, J.A., Happ, G.M., Ollier, W.E., Polvi, A., Thomson, W., Wagner, J.L. Nomenclature for factors of the dog major histocompatibility system (DLA), 1998. First report of the ISAG DLA Nomenclature Committee. International Society for Animals Genetics. Tissue Antigens 1999, 54, 312–321.
   PubMedGoogle Scholar
• Hart, P.H., Vitti, G.F., Burgess, D.R., Whitty, G.A., Piccoli, D.S., Hamilton, J.A. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor alpha, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 1989, 86, 3803–3807.
   PubMed Web of Science ®Google Scholar